Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study

M.   Yu. Fedyanin; Федянин М. Ю.; L.  Yu.  Vladimirova; Владимирова Л. Ю.; V.  A.  Chubenko; Чубенко В. А.; L.   A. Zagorskaya; Загорская Л. А.; A.  V.  Belyaeva; Беляева А. В.; O.  L.  Fakhrutdinova; Фахрутдинова О. Л.; S.  A.  Belukhin; Белухин С. А.; A.   S. Zhabina; Жабина А. С.; L.   V. Khalikova; Халикова Л. В.; L.  V.  Bolotina; Болотина Л. В.; R.   V. Orlova; Орлова Р. В.; F.  V.  Moiseenko; Моисеенко Ф. В.; G.   Z. Mukhametshina; Мухаметшина Г. З.; A.  I.  Khasanova; Хасанова А. И.; A.  V.  Belonogov; Белоногов А. В.; Kh.  S.  Musaeva; Мусаева Х. С.; O.  Yu.  Novikova; Новикова О. Ю.; I.  Yu.  Stradaeva; Страдаева И. Ю.; I.  L.  Popova; Попова И. Л.; S.  P.  Erdniev; Эрдниев С. П.; A.  K.  Ivanova; Иванова А. К.; A.  V.  Androsova; Андросова А. В.; P.  S.  Feoktistova; Феоктистова П. С.; E.  S.  Kuzmina; Кузьмина Е. С.; E.   V. Karabina; Карабина Е. В.; O.  V.  Nekrasova; Некрасова О. В.; O.  V.  Sekhina; Сехина О. В.; A.   A. Mishchenko; Мищенко А. А.; L.  A.  Mukova; Мукова Л. А.; B.  Kh.  Kertiev; Кертиев Б. Х.; G.  I.  Kosar; Косарь Г. И.; S.   N. Osodoeva; Осодоева С. Н.; A.  I.  Kats; Кац А. И.; R.  R.  Malina; Малина Р. Р.; M.  A.  Lyadova; Лядова М. А.; A.  A.  Tryakin; Трякин А. А.; S.  A.  Tyulandin; Тюляндин С. А.

doi:10.17650/2686-9594-2021-11-3-4-11-17

Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study

Authors: Fedyanin M..¹, Vladimirova L.Y.², Chubenko V.A.³, Zagorskaya L.A.³, Belyaeva A.V.³, Fakhrutdinova O.L.³, Belukhin S.A.³, Zhabina A.S.³, Khalikova L.V.³, Bolotina L.V.⁴, Orlova R.V.⁵, Moiseenko F.V.³^,5, Mukhametshina G.Z.⁶, Khasanova A.I.⁶, Belonogov A.V.⁷, Musaeva K.S.⁸, Novikova O.Y.⁹, Stradaeva .Y.¹⁰, Popova I.L.¹¹, Erdniev S.P.¹¹, Ivanova A.K.¹¹, Androsova A.V.¹¹, Feoktistova P.S.¹², Kuzmina E.S.¹³, Karabina E.V.¹⁴, Nekrasova O.V.¹⁵, Sekhina O.V.¹⁶, Mishchenko A.A.¹⁷, Mukova L.A.¹⁸, Kertiev B.K.¹⁸, Kosar G.I.¹⁹, Osodoeva S.N.²⁰, Kats A.I.¹⁹, Malina R.R.¹⁹, Lyadova M.A.²¹, Tryakin A.A.¹, Tyulandin S..¹
Affiliations:
1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2. National Medical Research Center of Oncology, Ministry of Health of Russia
3. Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
4. P. A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
5. Saint Petersburg State University
6. Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Tatarstan
7. Medsi Group of Companies, Clinical Hospital No. 1 «Medsi»
8. Republican Oncology Dispensary
9. Regional Clinical Oncology Center
10. Moscow Regional Oncology Dispensary
11. Saint Petersburg Clinical Oncology Dispensary
12. Nizhnevartovsk Oncology Dispensary
13. Salekhard Regional Clinical Hospital
14. Tula Regional Oncology Dispensary
15. Multicare Medical Center “Medical City”
16. Oncology Dispensary No. 5, Moscow Healthcare Department
17. Primorsky Regional Oncology Dispensary
18. Oncology Dispensary, Ministry of Health of Kabardino-Balkar Republic
19. Oncology Dispensary
20. Buryat Republican Oncology Dispensary
21. City Clinical Oncology Hospital No. 1 Moscow Healthcare Department
Issue: Vol 11, No 3-4 (2021)
Pages: 11-17
Section: ORIGINAL REPORT
Published: 15.03.2022
URL: https://onco-surgery.info/jour/article/view/518
DOI: https://doi.org/10.17650/2686-9594-2021-11-3-4-11-17
ID: 518

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Objective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic colon cancer.
Materials and methods. we performed a retrospective analysis of data on patients with metastatic colon cancer treated in 9 clinics in the Russian federation. The inclusion criteria were as follows: metastatic or locally advanced colon cancer; treatment with bevacizumab or aflibercept plus fOLfIRI in the second-line therapy. The primary outcome measure was progression-free survival (PfS). Secondary outcome measures included objective response rate and incidence of adverse events.
Results. A total of 271 patients with metastatic colon cancer who received second-line therapy with bevacizumab (n = 81) or aflibercept (n = 190) between 2014 and 2018 were selected for this study. Study groups were matched for main prognostic signs. The objective response rate was 18.1 % in the bevacizumab group and 20.5 % in the aflibercept group (p = 0.7). The median PfS was 5 months (95 % confidence interval 3.8–6.1) in the aflibercept group and 7 months (95 % confidence interval 0.81–2.1) in the bevacizumab group (hazard ratio 1.4; 95 % confidence interval 0.99–2.1; p = 0.04). multivariate regression analysis demonstrated that the type of the targeted drug independently had no effect on PfS (hazard ratio 1.3; 95 % confidence interval 0.9–1.9; p = 0.2). we observed no statistically significant differences in the incidence of complications of any grades between the groups (58 % vs 72 %, p = 0.1). Patients receiving aflibercept were more likely to develop grade III–Iv arterial hypertension (2 % vs 9.5 %) and diarrhea (0 % vs 5.4 %), whereas thrombotic complications were more common in the bevacizumab group (10 % vs 1.8 %).
Conclusion. we observed no significant differences in objective response rate and PfS between patients with metastatic colon cancer receiving bevacizumab or aflibercept in combination with fOLfIRI as second-line therapy. The toxicity profiles were different. Our findings can be used for choosing an optimal targeted drug for second-line treatment.

Keywords

colon cancer, chemotherapy, aflibercept, bevacizumab, population-based study

About the authors

M. Yu. Fedyanin

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: fedianinmu@mail.ru
ORCID iD: 0000-0001-5615-7806

Mikhail Yuryevich Fedyanin

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

L. Yu. Vladimirova

National Medical Research Center of Oncology, Ministry of Health of Russia

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study

Full Text

Abstract

Keywords

About the authors

References

Supplementary files